fluorouracil has been researched along with Brain Diseases in 43 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Brain Diseases: Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hyperammonemia or hyperammonemic leukoencephalopathy sometimes occurs as an adverse event after 5-fluorouracil (5-FU) chemotherapy." | 7.74 | The aggravating factors of hyperammonemia related to 5-fluorouracil infusion--a report of two cases. ( Asakage, T; Kikuta, S; Kubota, A; Nakao, K; Sugasawa, M, 2008) |
| "We observed leukoencephalopathy in 1 patient, and progressive dementia in another, during the administration of 5-fluorouracil (5-FU) and levamisole." | 7.69 | Disabling encephalopathy during 5-fluorouracil and levamisole adjuvant therapy for resected colorectal cancer: a report of two cases. ( Dobranowski, J; Fawcet, SE; Figueredo, AT; Molloy, DW; Paulseth, JE, 1995) |
| "Azotemia, body fluid insufficiency and bacterial infections were frequently found in these patients." | 5.30 | Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. ( Chang, HK; Chen, JS; Liaw, CC; Liaw, SJ; Lin, YC; Wang, CH; Wang, HM; Yang, TS; Yeh, CT, 1999) |
| "We report a patient who developed multifocal cerebral demyelination with the use of 5-fluorouracil, levamisole, and leucovorin as adjuvant treatment for intestinal adenocarcinoma." | 4.79 | Cerebral demyelination with 5-fluorouracil and levamisole. ( Fassas, AB; Gattani, AM; Morgello, S, 1994) |
| "Hyperammonemia or hyperammonemic leukoencephalopathy sometimes occurs as an adverse event after 5-fluorouracil (5-FU) chemotherapy." | 3.74 | The aggravating factors of hyperammonemia related to 5-fluorouracil infusion--a report of two cases. ( Asakage, T; Kikuta, S; Kubota, A; Nakao, K; Sugasawa, M, 2008) |
| "Carmofur (1-hexylcarbamyl-5-fluorouracil), a derivative of 5-fluorouracil (5-FU), has been widely used in Japan as a postoperative adjuvant chemotherapy agent for colorectal and breast cancer." | 3.71 | Diffusion-weighted MR imaging of Carmofur-induced leukoencephalopathy. ( Fujikawa, A; Hachiya, J; Katase, S; Kurosaki, Y; Tsuchiya, K, 2001) |
| "We observed leukoencephalopathy in 1 patient, and progressive dementia in another, during the administration of 5-fluorouracil (5-FU) and levamisole." | 3.69 | Disabling encephalopathy during 5-fluorouracil and levamisole adjuvant therapy for resected colorectal cancer: a report of two cases. ( Dobranowski, J; Fawcet, SE; Figueredo, AT; Molloy, DW; Paulseth, JE, 1995) |
| "The use of 5-fluorouracil (5-FU) and levamisole in patients with Stage III adenocarcinoma of the colon has now become standard." | 3.69 | Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole. The use of thallium SPECT imaging to assist in noninvasive diagnosis--a case report. ( Gordon, J; Licho, R; Litofsky, NS; Ragland, R; Recht, L; Savarese, DM; Smith, TW, 1996) |
| " Hyperammonemia induced by 5-FU is relatively rare, with a reported incidence of 5-9%; however, caution is required with high dosage regimens of 5-FU that are currently recommended for colorectal cancer therapy because hyperammonemia is an important side effect." | 2.58 | [A Case of Recurrent Hyperammonemic Encephalopathy during Adjuvant Chemotherapy(Modified FOLFOX6)for Colorectal Cancer]. ( Funahashi, K; Kagami, S; Tamura, A; Yoshino, Y, 2018) |
| "Leucoencephalopathy caused by antineoplastic drugs was reviewed." | 2.44 | [Leukoencephalopathy caused by antineoplastic drugs]. ( Mizutani, T, 2008) |
| " Each chemotherapeutic drug has the potential to induce various adverse events in the patients receiving chemotherapy." | 2.41 | [Prevention and treatment for adverse events induced by chemotherapy]. ( Tsukuda, M, 2002) |
| "Because recurrent gastric cancer is often a progressive condition, post-treatment might be promptly transferred to the other posterior regimen without 5-FU as required." | 1.72 | [Hyperammonemic encephalopathy after treatment with modified FOLFOX6 regimen for recurrent gastric cancer:a case report]. ( Hirano, S; Ichinokawa, M; Kumagai, K; Kuwabara, S; Matsumoto, J; Murakawa, K; Ono, K; Takeuchi, Y; Wada, H, 2022) |
| "Idiopathic hyperammonemic encephalopathy is a rare complication of chemotherapy, which has previously mainly been associated with L-asparaginase, cytarabine and 5-FU." | 1.72 | Idiopathic hyperammonemic encephalopathy secondary to gemcitabine-cisplatin treatment. ( Huitema, ADR; Otten, HM; Verkerk, K, 2022) |
| "Following the diagnosis of RS rectal cancer with muc, pT4a, N3(14/15), M1c, P1, pStage Ⅳc, RAS/BRAF: wild type, treatment was initiated with mFOLFOX6 plus panitumumab(Pmab)." | 1.62 | [A Case of Hyperammonemic Encephalopathy following mFOLFOX6 plus Panitumumab Therapy for Rectal Cancer]. ( Eguchi, S; Fukuoka, T; Iseki, Y; Lee, S; Miki, Y; Muguruma, K; Nagahara, H; Ohira, M; Shibutani, M; Tamura, T; Tanaka, H; Toyokawa, T; Tsujio, G; Yashiro, M; Yoshii, M, 2021) |
| "5-FU-induced hyperammonaemic encephalopathy started 2 [1-4] days after 5-FU infusion onset." | 1.56 | 5-Fluorouracil-induced hyperammonaemic encephalopathy: A French national survey. ( Boige, V; Boilève, A; Chouchana, L; Ducreux, M; Gaboriau, L; Hillaire-Buys, D; Hollebecque, A; Jozwiak, M; Lillo-Le Louët, A; Malka, D; Thomas, L, 2020) |
| "Here we describe a case of 5-FU encephalopathy in gastric cancer with an atypical reversible diffusion-restricted lesion on MR imaging, showing bilateral basal ganglia, thalami, and parasagittal frontal cortex involvement on diffusion and T2-weighted imaging." | 1.38 | Atypical diffusion-restricted lesion in 5-Fluorouracil encephalopathy. ( Kim, JS; Kwon, HM; Lee, WW; Son, KR, 2012) |
| "Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) chemotherapy and is licensed for the treatment of breast and gastrointestinal cancers." | 1.35 | Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion. ( Kolluri, RB; Raouf, S; Tipples, K, 2009) |
| "First, the patient developed severe encephalopathy following a high-dose chemotherapy protocol commonly used in the treatment of metastatic breast carcinoma and second, the encephalopathy involved primarily deep gray matter structures rather than white matter." | 1.32 | Fatal chemotherapy-induced encephalopathy following high-dose therapy for metastatic breast cancer: a case report and review of the literature. ( Cossaart, N; Johnson, P; Preston, D; SantaCruz, KS; Skikne, BS, 2003) |
| "Azotemia, body fluid insufficiency and bacterial infections were frequently found in these patients." | 1.30 | Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. ( Chang, HK; Chen, JS; Liaw, CC; Liaw, SJ; Lin, YC; Wang, CH; Wang, HM; Yang, TS; Yeh, CT, 1999) |
| "Patients with decreased dihydropyrimidine dehydrogenase (DPD) activity are at increased risk for experiencing serious adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy." | 1.29 | Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. ( Allegra, CJ; Cantilena, LR; Chu, E; Diasio, RB; Grem, JL; Larson, LV; Liang, MD; Lu, ZH; Takimoto, CH; Zhang, R, 1996) |
| " Even so, HCFU should be dosed when needed in spite of this risk." | 1.27 | [A case of leukoencephalopathy caused by HCFU]. ( Abe, S; Kamata, H; Kisida, S; Miyagawa, N; Murakami, A; Nagano, H; Ueda, K; Yasui, H, 1988) |
| "A case of toxic leucoencephalopathy induced by 5 FU derivatives is reported." | 1.27 | [A case of toxic leucoencephalopathy induced by 5FU derivatives]. ( Ishijima, B; Mizutani, T; Morimatsu, Y; Sato, J; Yasue, M, 1985) |
| " Gastrointestinal and hematologic toxic effects were mild and infrequent." | 1.26 | High-dose allopurinol modulation of 5-FU toxicity: phase I trial of an outpatient dose schedule. ( Campbell, TN; House, BA; Howell, SB; Pfeifle, C, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (20.93) | 18.7374 |
| 1990's | 11 (25.58) | 18.2507 |
| 2000's | 10 (23.26) | 29.6817 |
| 2010's | 7 (16.28) | 24.3611 |
| 2020's | 6 (13.95) | 2.80 |
| Authors | Studies |
|---|---|
| Kuwabara, S | 1 |
| Murakawa, K | 1 |
| Kumagai, K | 1 |
| Takeuchi, Y | 1 |
| Wada, H | 1 |
| Ichinokawa, M | 1 |
| Matsumoto, J | 1 |
| Ono, K | 1 |
| Hirano, S | 1 |
| Tsujio, G | 1 |
| Muguruma, K | 1 |
| Eguchi, S | 1 |
| Iseki, Y | 1 |
| Miki, Y | 1 |
| Yoshii, M | 1 |
| Fukuoka, T | 1 |
| Tamura, T | 1 |
| Shibutani, M | 1 |
| Nagahara, H | 1 |
| Toyokawa, T | 1 |
| Tanaka, H | 1 |
| Lee, S | 1 |
| Yashiro, M | 1 |
| Ohira, M | 1 |
| Furuyama, T | 1 |
| Enjoji, M | 1 |
| Yamato, M | 1 |
| Kondo, I | 1 |
| Hinokida, M | 1 |
| Tatsutomi, Y | 1 |
| Nakazawa, K | 1 |
| Nagayama, K | 1 |
| Ushirokoji, Y | 1 |
| Verkerk, K | 1 |
| Otten, HM | 1 |
| Huitema, ADR | 1 |
| Boilève, A | 2 |
| Thomas, L | 1 |
| Lillo-Le Louët, A | 1 |
| Gaboriau, L | 1 |
| Chouchana, L | 1 |
| Ducreux, M | 2 |
| Malka, D | 2 |
| Boige, V | 1 |
| Hollebecque, A | 2 |
| Hillaire-Buys, D | 1 |
| Jozwiak, M | 2 |
| Yano, Y | 1 |
| Kuriyama, A | 1 |
| Miaris, N | 1 |
| Sgouros, J | 1 |
| Gerolympou, M | 1 |
| Spyropoulos, B | 1 |
| Drakopoulos, D | 1 |
| Gkoura, S | 1 |
| Res, H | 1 |
| Samantas, E | 1 |
| Nguyen, MT | 1 |
| Stoianovici, R | 1 |
| Brunetti, L | 1 |
| Yoshino, Y | 1 |
| Tamura, A | 1 |
| Kagami, S | 1 |
| Funahashi, K | 1 |
| Wicker, C | 1 |
| Verret, B | 1 |
| Leroy, F | 1 |
| Pontoizeau, C | 1 |
| Ottolenghi, C | 1 |
| De Lonlay, P | 1 |
| Nakagami, R | 1 |
| Yamaguchi, M | 1 |
| Ezawa, K | 1 |
| Kimura, S | 1 |
| Hamamichi, S | 1 |
| Sekine, N | 1 |
| Furukawa, A | 1 |
| Niitsu, M | 1 |
| Fujii, H | 1 |
| Tipples, K | 1 |
| Kolluri, RB | 1 |
| Raouf, S | 1 |
| Advani, PP | 1 |
| Fakih, MG | 1 |
| Lee, WW | 1 |
| Kim, JS | 1 |
| Son, KR | 1 |
| Kwon, HM | 1 |
| Tsukuda, M | 1 |
| Cossaart, N | 1 |
| SantaCruz, KS | 1 |
| Preston, D | 1 |
| Johnson, P | 1 |
| Skikne, BS | 1 |
| Ishibashi, S | 1 |
| Nishimura, H | 1 |
| Mizusawa, H | 1 |
| Lukaschek, J | 1 |
| Nufer, M | 1 |
| Maurer, D | 1 |
| Asanger, M | 1 |
| Honegger, H | 1 |
| Widmer, L | 1 |
| Malet-Martino, M | 1 |
| Legay, R | 1 |
| Martino, R | 1 |
| Mémain, N | 1 |
| Angellier, JF | 1 |
| Obadia, E | 1 |
| Angellier, E | 1 |
| Chelha, R | 1 |
| Couprie, R | 1 |
| Kikuta, S | 1 |
| Asakage, T | 1 |
| Nakao, K | 1 |
| Sugasawa, M | 1 |
| Kubota, A | 1 |
| Mizutani, T | 2 |
| Maisin, H | 1 |
| Anckaert, MA | 1 |
| De Coster, BM | 1 |
| Bertino, JR | 1 |
| Campbell, TN | 1 |
| Howell, SB | 1 |
| Pfeifle, C | 1 |
| House, BA | 1 |
| Stéphan, F | 1 |
| Etienne, MC | 1 |
| Wallays, C | 1 |
| Milano, G | 1 |
| Clergue, F | 1 |
| Figueredo, AT | 1 |
| Fawcet, SE | 1 |
| Molloy, DW | 1 |
| Dobranowski, J | 1 |
| Paulseth, JE | 1 |
| Enterline, DS | 1 |
| Davey, NC | 1 |
| Tien, RD | 1 |
| Yeh, KH | 2 |
| Cheng, AL | 2 |
| Fassas, AB | 1 |
| Gattani, AM | 1 |
| Morgello, S | 1 |
| Savarese, DM | 1 |
| Gordon, J | 1 |
| Smith, TW | 1 |
| Litofsky, NS | 1 |
| Licho, R | 1 |
| Ragland, R | 1 |
| Recht, L | 1 |
| Valik, D | 1 |
| Takimoto, CH | 1 |
| Lu, ZH | 1 |
| Zhang, R | 1 |
| Liang, MD | 1 |
| Larson, LV | 1 |
| Cantilena, LR | 1 |
| Grem, JL | 1 |
| Allegra, CJ | 1 |
| Diasio, RB | 1 |
| Chu, E | 1 |
| Liaw, CC | 1 |
| Wang, HM | 1 |
| Wang, CH | 1 |
| Yang, TS | 1 |
| Chen, JS | 1 |
| Chang, HK | 1 |
| Lin, YC | 1 |
| Liaw, SJ | 1 |
| Yeh, CT | 1 |
| Osako, Y | 1 |
| Fujikawa, A | 1 |
| Tsuchiya, K | 1 |
| Katase, S | 1 |
| Kurosaki, Y | 1 |
| Hachiya, J | 1 |
| Yamada, T | 1 |
| Okamura, S | 1 |
| Okazaki, T | 1 |
| Ushiroyama, T | 1 |
| Yanagawa, Y | 1 |
| Ueki, M | 1 |
| Sugimoto, O | 1 |
| Yamazaki, H | 1 |
| Sugino, M | 1 |
| Masui, Y | 1 |
| Fosså, SD | 1 |
| Dahl, O | 1 |
| Hoel, R | 1 |
| Heier, M | 1 |
| Loeb, M | 1 |
| Kamata, H | 1 |
| Murakami, A | 1 |
| Miyagawa, N | 1 |
| Yasui, H | 1 |
| Nagano, H | 1 |
| Abe, S | 1 |
| Ueda, K | 1 |
| Kisida, S | 1 |
| Yasue, M | 1 |
| Ishijima, B | 1 |
| Sato, J | 1 |
| Morimatsu, Y | 1 |
| Weiss, HD | 1 |
| Walker, MD | 1 |
| Wiernik, PH | 1 |
| Diem, E | 1 |
| Fritsch, P | 1 |
6 reviews available for fluorouracil and Brain Diseases
| Article | Year |
|---|---|
[A Case of Recurrent Hyperammonemic Encephalopathy during Adjuvant Chemotherapy(Modified FOLFOX6)for Colorectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Chemotherapy, Adjuvant; Colon, Ascen | 2018 |
[Prevention and treatment for adverse events induced by chemotherapy].
Topics: Anaphylaxis; Antineoplastic Agents; Brain Diseases; Cisplatin; Docetaxel; Fluorouracil; Humans; Neop | 2002 |
[Leukoencephalopathy caused by antineoplastic drugs].
Topics: Antineoplastic Agents; Brain Diseases; Fluorouracil | 2008 |
Cerebral demyelination with 5-fluorouracil and levamisole.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Colorec | 1994 |
Leukoencephalopathy following treatment with carmofur: a case report and review of the Japanese literature.
Topics: Antineoplastic Agents; Brain Diseases; Female; Fluorouracil; Humans; Japan; Middle Aged | 1989 |
Neurotoxicity of commonly used antineoplastic agents (first of two parts).
Topics: Animals; Antineoplastic Agents; Asparaginase; Brain; Brain Diseases; Fluorouracil; Humans; Leukemia; | 1974 |
37 other studies available for fluorouracil and Brain Diseases
| Article | Year |
|---|---|
[Hyperammonemic encephalopathy after treatment with modified FOLFOX6 regimen for recurrent gastric cancer:a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Female; Fluorouracil; Humans; Hypera | 2022 |
[A Case of Hyperammonemic Encephalopathy following mFOLFOX6 plus Panitumumab Therapy for Rectal Cancer].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Fluorouracil; Hum | 2021 |
[A Case of Severe Hyperammonemic Encephalopathy in a Dialysis Patient Following mFOLFOX6 Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Fluorouracil; Humans; Hyperamm | 2021 |
Idiopathic hyperammonemic encephalopathy secondary to gemcitabine-cisplatin treatment.
Topics: Antineoplastic Agents; Asparaginase; Brain Diseases; Cisplatin; Cytarabine; Deoxycytidine; Fluoroura | 2022 |
5-Fluorouracil-induced hyperammonaemic encephalopathy: A French national survey.
Topics: Aged; Ammonia; Antimetabolites, Antineoplastic; Brain Diseases; Citric Acid Cycle; Dose-Response Rel | 2020 |
5-Fluorouracil-induced encephalopathy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Female; Fluorouracil; Humans; | 2020 |
Posterior Reversible Encephalopathy Syndrome During Treatment with Aflibercept, 5-Fluorouracil, Leucovorin, and Irinotecan for Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Colorectal Neoplasms; Female; Fluoro | 2019 |
Chemotherapy induced stroke mimic: 5-Fluorouracil encephalopathy fulfilling criteria for tissue plasminogen activator therapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aphasia; Brain Dise | 2017 |
5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Diseases; Female; Fluorour | 2019 |
Recovery correction technique for NMR spectroscopy of perchloric acid extracts using DL-valine-2,3-d2: validation and application to 5-fluorouracil-induced brain damage.
Topics: Animals; Brain; Brain Diseases; Creatine; Fluorouracil; Magnetic Resonance Spectroscopy; Perchlorate | 2014 |
Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 2009 |
5-FU-induced hyperammonemic encephalopathy in a case of metastatic rectal adenocarcinoid successfully rechallenged with the fluoropyrimidine analog, capecitabine.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Brain Diseases; Capecitabine; Deoxycytidine; | 2011 |
Atypical diffusion-restricted lesion in 5-Fluorouracil encephalopathy.
Topics: Antimetabolites, Antineoplastic; Brain; Brain Diseases; Diffusion Magnetic Resonance Imaging; Fluoro | 2012 |
Fatal chemotherapy-induced encephalopathy following high-dose therapy for metastatic breast cancer: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain; Brain Diseases; Breast Neoplas | 2003 |
5-FU-induced acute leukoencephalopathy.
Topics: Acute Disease; Adenocarcinoma; Antimetabolites, Antineoplastic; Brain Diseases; Colonic Neoplasms; F | 2004 |
Cardiotoxicity and neurotoxicity of high-dose continuous fluorouracil as a result of degradation compounds in the drug vials.
Topics: Acetaldehyde; Aged; Antimetabolites, Antineoplastic; Brain Diseases; Carcinoma; Chemistry, Pharmaceu | 2004 |
[Fatal acute encephalopathy due to 5-fluorouracil treatment].
Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brai | 2005 |
The aggravating factors of hyperammonemia related to 5-fluorouracil infusion--a report of two cases.
Topics: Brain Diseases; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorouracil; Humans; Hypera | 2008 |
[Combination chemotherapy and radiotherapy. Differential effect, on the medullary syndrome, of fractionated irradiation with fractionated drug administration].
Topics: Animals; Brain Diseases; Disease Models, Animal; Drug Administration Schedule; Female; Fluorouracil; | 1982 |
Clinical use of methotrexate--with emphasis on use of high doses.
Topics: Animals; Asparaginase; Brain Diseases; Child, Preschool; Cisplatin; Cytarabine; Drug Administration | 1981 |
High-dose allopurinol modulation of 5-FU toxicity: phase I trial of an outpatient dose schedule.
Topics: Adenocarcinoma; Aged; Allopurinol; Brain Diseases; Drug Administration Schedule; Drug Evaluation; Dr | 1982 |
Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Brain Diseases; Cecal Neoplasms; Dihydrourac | 1995 |
Disabling encephalopathy during 5-fluorouracil and levamisole adjuvant therapy for resected colorectal cancer: a report of two cases.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Diseases; Chemoth | 1995 |
Neuroradiology case of the day. Multifocal inflammatory leukoencephalopathy due to treatment with 5-fluorouracil and levamisole.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Colonic Neoplasms; Demyelinating Dis | 1995 |
Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid.
Topics: Acute Disease; Brain Diseases; Coma; Confusion; Fluorouracil; Humans; Leucovorin; Male; Middle Aged | 1994 |
Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole. The use of thallium SPECT imaging to assist in noninvasive diagnosis--a case report.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Brain Diseases; Colonic Neoplasms; Demyelinati | 1996 |
High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy.
Topics: Acidosis; Ammonia; Antimetabolites, Antineoplastic; Brain Diseases; Coma; Diagnosis, Differential; E | 1997 |
Encephalopathy, lactic acidosis, hyperammonaemia and 5-fluorouracil toxicity.
Topics: Acidosis, Lactic; Ammonia; Brain Diseases; Chemical and Drug Induced Liver Injury; Citric Acid Cycle | 1998 |
Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency.
Topics: Brain Diseases; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Male; Middle Aged; Oxidore | 1996 |
Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bacterial Infections; Brain Diseases; Dehydration; Fem | 1999 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 24-1999. Neurologic disorder in a 65-year-old man after treatment of colon cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Diseases; Cogniti | 1999 |
[A case of reversible carmofur-induced leukoencephalopathy].
Topics: Adult; Antineoplastic Agents; Brain; Brain Diseases; Breast Neoplasms; Female; Fluorouracil; Humans; | 2001 |
Diffusion-weighted MR imaging of Carmofur-induced leukoencephalopathy.
Topics: Adult; Antineoplastic Agents; Brain; Brain Diseases; Breast Neoplasms; Carcinoma, Ductal, Breast; Ch | 2001 |
Doxifluridine (5'-dFUrd) in patients with advanced colorectal carcinoma. A phase II study.
Topics: Angina Pectoris; Brain Diseases; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Evaluation; Elect | 1985 |
[A case of leukoencephalopathy caused by HCFU].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; B | 1988 |
[A case of toxic leucoencephalopathy induced by 5FU derivatives].
Topics: Antineoplastic Agents; Brain; Brain Diseases; Breast Neoplasms; Female; Fluorouracil; Humans; Middle | 1985 |
[Xeroderma pigmentosum, universal alopecia and associated neuro-ocular symptoms].
Topics: Administration, Topical; Alopecia; Brain Diseases; Fluorouracil; Glaucoma; Humans; Male; Middle Aged | 1973 |